• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to project page

2017 Fiscal Year Final Research Report

Development of fusion peptides of beta-hairpin peptides and survivin binding molecules as cancer-specific internal radiotherapeutic agents

Research Project

  • PDF
Project/Area Number 15K09895
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Research Field Radiation science
Research InstitutionNagasaki University

Principal Investigator

FUCHIGAMI Takeshi  長崎大学, 医歯薬学総合研究科(薬学系), 准教授 (30432206)

Co-Investigator(Kenkyū-buntansha) 大庭 誠  長崎大学, 医歯薬学総合研究科(薬学系), 准教授 (20396716)
吉田 さくら  長崎大学, 医歯薬学総合研究科(薬学系), 助教 (40736419)
中山 守雄  長崎大学, 医歯薬学総合研究科(薬学系), 教授 (60164373)
Project Period (FY) 2015-04-01 – 2018-03-31
Keywords薬学 / 放射線 / 内用放射線療法 / 癌
Outline of Final Research Achievements

In this study, we aimed to develop radiopharmaceuticals targeting survivin with the aim of developing internal radiotherapeutic agents that can be applied to nearly all cancers and show high selective effects on cancer tissues. Therefore, we designed survivin target peptides using cationic β-hairpin peptides (CHPs) as cancer cell carriers.
Within the research period, we succeeded in developing several peptides that bind to survivin with a completely new mechanism and found r9-INC-7c with stronger antitumor activity than reported a low molecular compound (S12). We also developed SVS-1 derivatives with high selectivity for cancer cells. In the future, we plan to develop fusion peptides of SVS-1 derivatives and survivin binding molecules as cancer-specific internal radiotherapeutic agents.

Free Research Field

放射線科学

URL: 

Published: 2019-03-29  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi